Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 69

1.

Stable prevalence of transmitted drug resistance mutations and increased circulation of non-B subtypes in antiretroviral-naive chronically HIV-infected patients in 2015/2016 in France.

Assoumou L, Bocket L, Pallier C, Grude M, Ait-Namane R, Izopet J, Raymond S, Charpentier C, Visseaux B, Wirden M, Trabaud MA, Le Guillou-Guillemette H, Allaoui C, Henquell C, Krivine A, Dos Santos G, Delamare C, Bouvier-Alias M, Montes B, Ferre V, De Monte A, Signori-Schmuck A, Maillard A, Morand-Joubert L, Tumiotto C, Fafi-Kremer S, Amiel C, Barin F, Marque-Juillet S, Courdavault L, Vallet S, Beby-Defaux A, de Rougemont A, Fenaux H, Avettand-Fenoel V, Allardet-Servent A, Plantier JC, Peytavin G, Calvez V, Chaix ML, Descamps D; ANRS AC-43 Resistance Study Group .

J Antimicrob Chemother. 2019 Feb 11. doi: 10.1093/jac/dkz011. [Epub ahead of print]

PMID:
30753724
2.

Low incidence of acute rejection within 6 months of kidney transplantation in HIV-infected recipients treated with raltegravir: the Agence Nationale de Recherche sur le Sida et les Hépatites Virales (ANRS) 153 TREVE trial.

Matignon M, Lelièvre JD, Lahiani A, Abbassi K, Desvaux D, Diallo A, Peraldi MN, Taburet AM, Saillard J, Delaugerre C, Costagliola D, Assoumou L, Grimbert P; ANRS 153 TREVE study group.

HIV Med. 2019 Mar;20(3):202-213. doi: 10.1111/hiv.12700. Epub 2019 Jan 27.

PMID:
30688008
3.

Diagnostic accuracy of noninvasive markers of steatosis, NASH and liver fibrosis in HIV-monoinfected individuals at-risk of non-alcoholic fatty liver disease (NAFLD): results from the ECHAM study.

Lemoine M, Assoumou L, De Wit S, Girard PM, Valantin MA, Katlama C, Necsoi C, Campa P, Huefner AD, Schulze Zur Wiesch J, Rougier H, Bastard JP, Stocker H, Mauss S, Serfaty L, Ratziu V, Menu Y, Schlue J, Behrens G, Bedossa P, Capeau J, Ingiliz P, Costagliola D.

J Acquir Immune Defic Syndr. 2018 Dec 12. doi: 10.1097/QAI.0000000000001936. [Epub ahead of print]

PMID:
30570529
4.

Accurate quantification of CXCR4-using HIV-1 variants by Illumina deep-sequencing.

Raymond S, Delaugerre C, Nicot F, Assoumou L, Lancar R, Beniguel L, Izopet J; ANRS 146 OPTIMAL study group.

AIDS. 2018 Oct 23;32(16):2429-2431. doi: 10.1097/QAD.0000000000001976.

PMID:
30102658
5.

Immediate Versus Deferred Switching From a Boosted Protease Inhibitor-based Regimen to a Dolutegravir-based Regimen in Virologically Suppressed Patients With High Cardiovascular Risk or Age ≥50 Years: Final 96-Week Results of the NEAT022 Study.

Gatell JM, Assoumou L, Moyle G, Waters L, Johnson M, Domingo P, Fox J, Martinez E, Stellbrink HJ, Guaraldi G, Masia M, Gompels M, De Wit S, Florence E, Esser S, Raffi F, Stephan C, Rockstroh J, Giacomelli A, Vera J, Bernardino JI, Winston A, Saumoy M, Gras J, Katlama C, Pozniak AL; European Network for AIDS Treatment 022 (NEAT022) Study Group .

Clin Infect Dis. 2019 Feb 1;68(4):597-606. doi: 10.1093/cid/ciy505.

PMID:
29912307
6.

Impact of Human Immunodeficiency Virus Type 1 Minority Variants on the Virus Response to a Rilpivirine-Based First-line Regimen.

Raymond S, Nicot F, Pallier C, Bellecave P, Maillard A, Trabaud MA, Morand-Joubert L, Rodallec A, Amiel C, Mourez T, Bocket L, Beby-Defaux A, Bouvier-Alias M, Lambert-Niclot S, Charpentier C, Malve B, Mirand A, Dina J, Le Guillou-Guillemette H, Marque-Juillet S, Signori-Schmuck A, Barin F, Si-Mohamed A, Avettand Fenoel V, Roussel C, Calvez V, Saune K, Marcelin AG, Rodriguez C, Descamps D, Izopet J; French National Agency for Research on AIDS and Viral Hepatitis (ANRS) AC11 Resistance Study Group .

Clin Infect Dis. 2018 May 2;66(10):1588-1594. doi: 10.1093/cid/cix1070.

PMID:
29244143
7.

Silent Cerebral Small-Vessel Disease Is Twice as Prevalent in Middle-Aged Individuals With Well-Controlled, Combination Antiretroviral Therapy-Treated Human Immunodeficiency Virus (HIV) Than in HIV-Uninfected Individuals.

Moulignier A, Savatovsky J, Assoumou L, Lescure FX, Lamirel C, Godin O, Valin N, Tubiana R, Canestri A, Roux P, Sadik JC, Salomon L, Abrivard M, Katlama C, Yazdanpanah Y, Pialoux G, Girard PM, Costagliola D; Microvascular Brain Retina and Kidney (MicroBREAK) Study Group .

Clin Infect Dis. 2018 May 17;66(11):1762-1769. doi: 10.1093/cid/cix1075.

PMID:
29244126
8.

Darunavir/ritonavir monotherapy at a low dose (600/100 mg/day) in HIV-1-infected individuals with suppressed HIV viraemia.

Seang S, Schneider L, Nguyen T, Lê MP, Soulie C, Calin R, Caby F, Valantin MA, Tubiana R, Assoumou L, Marcelin AG, Peytavin G, Katlama C.

J Antimicrob Chemother. 2018 Feb 1;73(2):490-493. doi: 10.1093/jac/dkx417.

PMID:
29216346
9.

Four-days-a-week antiretroviral maintenance therapy in virologically controlled HIV-1-infected adults: the ANRS 162-4D trial.

de Truchis P, Assoumou L, Landman R, Mathez D, Le Dû D, Bellet J, Amat K, Katlama C, Gras G, Bouchaud O, Duracinsky M, Abe E, Alvarez JC, Izopet J, Saillard J, Melchior JC, Leibowitch J, Costagliola D, Girard PM, Perronne C; ANRS 162-4D Study Group .

J Antimicrob Chemother. 2018 Mar 1;73(3):738-747. doi: 10.1093/jac/dkx434.

PMID:
29186458
10.

Switching from a ritonavir-boosted protease inhibitor to a dolutegravir-based regimen for maintenance of HIV viral suppression in patients with high cardiovascular risk.

Gatell JM, Assoumou L, Moyle G, Waters L, Johnson M, Domingo P, Fox J, Martinez E, Stellbrink HJ, Guaraldi G, Masia M, Gompels M, De Wit S, Florence E, Esser S, Raffi F, Pozniak AL; NEAT022 Study Group*.

AIDS. 2017 Nov 28;31(18):2503-2514. doi: 10.1097/QAD.0000000000001675.

11.

Risk of HIV transmission during combined ART initiation for HIV-infected persons with severe immunosuppression.

Supervie V, Assoumou L, Breban R, Lert F, Costagliola D, Pialoux G, Landman R, Girard PM, Slama L; IMEA 040 DATA Study Group.

J Antimicrob Chemother. 2017 Nov 1;72(11):3172-3176. doi: 10.1093/jac/dkx276.

PMID:
28961977
12.

Antiretroviral-treated HIV-1 patients can harbour resistant viruses in CSF despite an undetectable viral load in plasma.

Soulie C, Grudé M, Descamps D, Amiel C, Morand-Joubert L, Raymond S, Pallier C, Bellecave P, Reigadas S, Trabaud MA, Delaugerre C, Montes B, Barin F, Ferré V, Jeulin H, Alloui C, Yerly S, Signori-Schmuck A, Guigon A, Fafi-Kremer S, Haïm-Boukobza S, Mirand A, Maillard A, Vallet S, Roussel C, Assoumou L, Calvez V, Flandre P, Marcelin AG; ANRS AC11 Resistance Study Group.

J Antimicrob Chemother. 2017 Aug 1;72(8):2351-2354. doi: 10.1093/jac/dkx128.

PMID:
28472307
13.

Prevalence of HIV-1 drug resistance in treated patients with viral load >50 copies/mL: a 2014 French nationwide study.

Assoumou L, Charpentier C, Recordon-Pinson P, Grudé M, Pallier C, Morand-Joubert L, Fafi-Kremer S, Krivine A, Montes B, Ferré V, Bouvier-Alias M, Plantier JC, Izopet J, Trabaud MA, Yerly S, Dufayard J, Alloui C, Courdavault L, Le Guillou-Guillemette H, Maillard A, Amiel C, Vabret A, Roussel C, Vallet S, Guinard J, Mirand A, Beby-Defaux A, Barin F, Allardet-Servent A, Ait-Namane R, Wirden M, Delaugerre C, Calvez V, Chaix ML, Descamps D, Reigadas S; ANRS AC-11 Resistance Study Group.

J Antimicrob Chemother. 2017 Jun 1;72(6):1769-1773. doi: 10.1093/jac/dkx042.

PMID:
28333232
14.

Is gender a factor associated with initiation of antiretroviral therapy at the Ambulatory Treatment Centre of Brazzaville?

Herbas Ekat M, Assoumou L, Diafouka M.

Sante Publique. 2016 Oct 19;28(4):517-524. French.

PMID:
28155756
15.

Lack of effects of statins on high-density lipoprotein subfractions in HIV-1-infected patients receiving protease inhibitors.

Bittar R, Aslangul É, Giral P, Assoumou L, Valantin MA, Kalmykova O, Federspiel MC, Cherfils C, Costagliola D, Bonnefont-Rousselot D; ANRS 126 study group.

C R Biol. 2017 Feb;340(2):109-113. doi: 10.1016/j.crvi.2016.11.004. Epub 2016 Dec 20.

16.

Resilience and Life Expectations of Perinatally HIV-1 Infected Adolescents in France.

Funck-Brentano I, Assoumou L, Veber F, Moshous D, Frange P, Blanche S.

Open AIDS J. 2016 Nov 9;10:209-224. eCollection 2016.

17.

Population Pharmacokinetic Modeling of Tenofovir in the Genital Tract of Male HIV-Infected Patients.

Valade E, Bouazza N, Lui G, Illamola SM, Benaboud S, Treluyer JM, Cobat A, Foissac F, De Sousa Mendes M, Chenevier-Gobeaux C, Suzan-Monti M, Rouzioux C, Assoumou L, Viard JP, Urien S, Ghosn J, Hirt D.

Antimicrob Agents Chemother. 2017 Feb 23;61(3). pii: e02062-16. doi: 10.1128/AAC.02062-16. Print 2017 Mar.

18.

HIV-1-RNA in seminal plasma correlates with detection of HIV-1-DNA in semen cells, but not with CMV shedding, among MSM on successful antiretroviral regimens.

Gantner P, Assoumou L, Leruez-Ville M, David L, Suzan-Monti M, Costagliola D, Rouzioux C, Ghosn J; EVARIST ANRS EP 49 Study Group.

J Antimicrob Chemother. 2016 Nov;71(11):3202-3205. Epub 2016 Jul 17.

PMID:
27432601
19.

Phase II Trial of Lenalidomide in HIV-Infected Patients with Previously Treated Kaposi's Sarcoma: Results of the ANRS 154 Lenakap Trial.

Pourcher V, Desnoyer A, Assoumou L, Lebbe C, Curjol A, Marcelin AG, Cardon F, Gibowski S, Salmon D, Chennebault JM, Poizot-Martin I, Peytavin G, Boué F, Costagliola D.

AIDS Res Hum Retroviruses. 2017 Jan;33(1):1-10. doi: 10.1089/AID.2016.0069. Epub 2016 Sep 7.

PMID:
27405442
20.

Expression pattern of the CXCL12/CXCR4-CXCR7 trio in Kaposi sarcoma skin lesions.

Desnoyer A, Dupin N, Assoumou L, Carlotti A, Gaudin F, Deback C, Peytavin G, Marcelin AG, Boué F, Balabanian K, Pourcher V; ANRS 154 LENAKAP trial group.

Br J Dermatol. 2016 Dec;175(6):1251-1262. doi: 10.1111/bjd.14748. Epub 2016 Oct 12.

PMID:
27177037

Supplemental Content

Loading ...
Support Center